Blog

Neoadjuvant therapy for resectable pancreatic cancer suggested by Alan Burguete-Torres

Photo of Alan Burguete-Torres from dralanburguete.com

Oct 7, 2024, 16:42

Neoadjuvant therapy for resectable pancreatic cancer suggested by Alan Burguete-Torres

Alan Burguete-Torres, Gastrointestinal Cancer Specialist at Centro Médico Zambrano Hellion, shared a post on X:

“New study on neoadjuvant therapy for resectable pancreatic cancer shows no improvement in overall survival rates. This highlights the need for further research to optimize treatment strategies.”

Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials

Authors: Daniel Aliseda, Pablo Martí-Cruchaga, Gabriel Zozaya, Nuria Blanco, Mariano Ponz, Ana Chopitea, Javier Rodríguez, Eduardo Castañón, Fernando Pardo and Fernando Rotellar.

Source: Alan Burguete-Torres/X

Alan Burguete-Torres Ana Chopitea cancer cancer awareness cancer care Cancer research Daniel Aliseda Eduardo Castañón Fernando Pardo Fernando Rotellar fight against cancer Gabriel Zozaya Global fight against cancer Javier Rodríguez Mariano Ponz Nuria Blanco OncoDaily Oncology Pablo Martí-Cruchaga Pancreatic Cancer resectable pancreatic cancer

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity